<- Back to digest

JSES - 2026-11-09 - Journal Article

Cost-Effectiveness of Open Reduction Internal Fixation Versus Radial Head Arthroplasty for Mason III/IV Radial Head Fractures: A Decision Analytic Markov Model.

Kumar R, Salman SG, Bouras A, Rice SW, Shen O, Cheng C, Bhashyam AR

cost-effectivenessLOE IIIn = N/A — decision analytic model; base case derived from 15/23 (ORIF) and 20/22 (RHA) good-outcome probabilities from prior literature10-year model horizon with 3% annual discounting.

Topics

shoulder elbowhandtrauma
PMID: 43003380DOI: 10.1016/j.jse.2026.11.029View on PubMed ->

Key Takeaway

RHA for Mason III/IV radial head fractures yields an ICER of $9,627/QALY versus ORIF, remaining cost-effective in 94.6% of 10,000 probabilistic iterations at a $100,000/QALY willingness-to-pay threshold.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This Markov cost-utility model compared ORIF versus RHA for Mason III/IV radial head fractures over a 10-year horizon using 2025 Medicare payment benchmarks. ORIF accrued $16,795 and 7.045 QALYs; RHA accrued $19,242 and 7.299 QALYs, yielding an ICER of $9,627/QALY and incremental net monetary benefit of $22,970 at $100,000/QALY. RHA's cost-effectiveness advantage disappears when ORIF good-outcome probability reaches 85.7% or when initial clinical outcomes are equivalent.

Key Limitation

All transition probabilities, state utilities, and outcome timing are model assumptions rather than empirically derived from a prospective Mason III/IV cohort, meaning the base-case result is illustrative rather than definitive.

Original Abstract

BACKGROUND

Mason type III and IV comminuted radial head fractures present a treatment dilemma between open reduction internal fixation (ORIF) and radial head arthroplasty (RHA). Functional outcomes, implant complications, and later treatment options vary across patients. We evaluated the cost-effectiveness of these strategies under explicit clinical and economic assumptions.

METHODS

We constructed a 5-state Markov cost-utility model for a Mason III/IV fracture, using a 10-year horizon, 3% annual discounting, and US Medicare payment benchmarks. An illustrative base case used good outcome probabilities of 15/23 for ORIF and 20/22 for RHA. Time-zero allocation of follow-up outcomes, state utilities, and later transitions were assumptions. Index costs used verified 2025 Physician Fee Schedule and Hospital Outpatient Prospective Payment System rates. We performed one-way, probabilistic (10,000 iterations), breakeven, and structural sensitivity analyses.

RESULTS

ORIF accrued $16,795 and 7.045 quality-adjusted life years (QALYs); RHA accrued $19,242 and 7.299 QALYs. RHA's incremental cost-effectiveness ratio (ICER) was $9,627/QALY, with incremental net monetary benefit of $22,970 at $100,000/QALY. Allocating outcomes at year 2 yielded $14,880/QALY, assuming zero unmeasured early differential secondary-care costs. RHA was cost-effective in 94.6% of probabilistic iterations at $100,000/QALY. The breakeven ORIF good outcome probability was 85.7%. When initial clinical outcomes were equal, ORIF was less costly with equal QALYs.

CONCLUSION

The illustrative base case favored RHA under the assumed functional difference and utilities. Higher ORIF success, early convergence, or a treatment-specific utility burden could remove that preference. These conditional findings require validation with contemporary fracture-specific utility and treatment-pathway data.

LEVEL OF EVIDENCE

Level III; Economic and Decision Analysis.